tetano
Editor, Senior Moderator
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Dec 10;39(12):1636-1641. doi: 10.3760/cma.j.issn.0254-6450.2018.12.019.
[h=1][Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].[/h] [Article in Chinese; Abstract available in Chinese from the publisher]
Meng ZY[SUP]1[/SUP], Zhang JY[SUP]1[/SUP], Zhang ZG[SUP]1[/SUP], Luo D[SUP]1[/SUP], Yang XM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Objective: To evaluate the immunogenicity of inactivated quadrivalent influenza vaccine (QIV) in adults aged 18-64 years, through a Meta-analysis. Methods: Literature was retrieved by searching the Medline, Cochrane Library, Science Direct in the past decade. All the studies were under random control trial (RCT) and including data related to immunogenicity which involving sero-protection rate (SPR) and sero-conversion rate (SCR) of the QIV, versus inactivated trivalent influenza vaccine (TIV) in the population aged 18 to 64. Revman 5.3 software was employed to manipulate the pooled date of the included literature. Result: A total of 8 studies for the SPR and SCR of the shared strains (two A lineage and one B lineage) were included. There appeared no significant differences in the response rates between the two vaccines. As for QIV versus TIV (B/Yamagata), the pooled RR of the SPR for B/Victoria was 1.28 (95%CI: 1.08-1.51, P<0.05), with the pooled RR of the SCR for B/Victoria as 1.94 (95%CI: 1.50-2.50, P<0.05). For QIV versus TIV (B/Victoria), the pooled RR of the SPR for B/Yamagata as 1.10 (95%CI: 1.02-1.18, P<0.05), and the pooled RR of SCR for B/Yamagata as 1.99 (95%CI: 1.34-2.97, P<0.05). Conclusion: In the population aged 18-64 years, inactivated QIV was equivalently immunogenic against the shared three strains included in the activated TIV while a superior immunogenic effect was noticed in the vaccine strain which did not include the inactivated QIV.
[h=4]KEYWORDS:[/h] Immunogenicity; Influenza vaccine; Meta-analysis; Quadrivalent influenza vaccine; Random control trial; Vaccines, inactivated
PMID: 30572392
[h=1][Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].[/h] [Article in Chinese; Abstract available in Chinese from the publisher]
Meng ZY[SUP]1[/SUP], Zhang JY[SUP]1[/SUP], Zhang ZG[SUP]1[/SUP], Luo D[SUP]1[/SUP], Yang XM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Objective: To evaluate the immunogenicity of inactivated quadrivalent influenza vaccine (QIV) in adults aged 18-64 years, through a Meta-analysis. Methods: Literature was retrieved by searching the Medline, Cochrane Library, Science Direct in the past decade. All the studies were under random control trial (RCT) and including data related to immunogenicity which involving sero-protection rate (SPR) and sero-conversion rate (SCR) of the QIV, versus inactivated trivalent influenza vaccine (TIV) in the population aged 18 to 64. Revman 5.3 software was employed to manipulate the pooled date of the included literature. Result: A total of 8 studies for the SPR and SCR of the shared strains (two A lineage and one B lineage) were included. There appeared no significant differences in the response rates between the two vaccines. As for QIV versus TIV (B/Yamagata), the pooled RR of the SPR for B/Victoria was 1.28 (95%CI: 1.08-1.51, P<0.05), with the pooled RR of the SCR for B/Victoria as 1.94 (95%CI: 1.50-2.50, P<0.05). For QIV versus TIV (B/Victoria), the pooled RR of the SPR for B/Yamagata as 1.10 (95%CI: 1.02-1.18, P<0.05), and the pooled RR of SCR for B/Yamagata as 1.99 (95%CI: 1.34-2.97, P<0.05). Conclusion: In the population aged 18-64 years, inactivated QIV was equivalently immunogenic against the shared three strains included in the activated TIV while a superior immunogenic effect was noticed in the vaccine strain which did not include the inactivated QIV.
[h=4]KEYWORDS:[/h] Immunogenicity; Influenza vaccine; Meta-analysis; Quadrivalent influenza vaccine; Random control trial; Vaccines, inactivated
PMID: 30572392